GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuo Therapeutics Inc (OTCPK:AURX) » Definitions » E10

Nuo Therapeutics (Nuo Therapeutics) E10 : $-0.29 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nuo Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Nuo Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.020. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.29 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was -2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Nuo Therapeutics was 31.70% per year. The lowest was -17.00% per year. And the median was 5.50% per year.

As of today (2024-05-26), Nuo Therapeutics's current stock price is $0.78. Nuo Therapeutics's E10 for the quarter that ended in Mar. 2024 was $-0.29. Nuo Therapeutics's Shiller PE Ratio of today is .


Nuo Therapeutics E10 Historical Data

The historical data trend for Nuo Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuo Therapeutics E10 Chart

Nuo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.27 -0.30 -0.30 -0.29

Nuo Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.30 -0.30 -0.29 -0.29

Competitive Comparison of Nuo Therapeutics's E10

For the Biotechnology subindustry, Nuo Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuo Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nuo Therapeutics's Shiller PE Ratio falls into.



Nuo Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nuo Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.02/131.7762*131.7762
=-0.020

Current CPI (Mar. 2024) = 131.7762.

Nuo Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201312 -0.050 98.326 -0.067
201403 -0.050 99.695 -0.066
201406 -0.090 100.560 -0.118
201409 -0.040 100.428 -0.052
201412 0.023 99.070 0.031
201503 0.020 99.621 0.026
201506 -0.010 100.684 -0.013
201509 -0.110 100.392 -0.144
201512 -0.340 99.792 -0.449
201603 -0.040 100.470 -0.052
201606 0.000 101.688 0.000
201609 -0.190 101.861 -0.246
201612 0.000 101.863 0.000
201703 -0.170 102.862 -0.218
201706 -0.390 103.349 -0.497
201709 -0.090 104.136 -0.114
201712 -0.352 104.011 -0.446
201803 -0.030 105.290 -0.038
201806 -0.030 106.317 -0.037
201809 -0.030 106.507 -0.037
201812 0.010 105.998 0.012
201903 -0.030 107.251 -0.037
201906 -0.020 108.070 -0.024
201909 -0.004 108.329 -0.005
201912 0.000 108.420 0.000
202009 -0.001 109.815 -0.001
202012 0.280 109.897 0.336
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 -0.029 117.630 -0.032
202203 -0.010 121.301 -0.011
202206 -0.020 125.017 -0.021
202209 -0.020 125.227 -0.021
202212 -0.020 125.222 -0.021
202303 -0.020 127.348 -0.021
202306 -0.020 128.729 -0.020
202309 -0.020 129.860 -0.020
202312 -0.020 129.419 -0.020
202403 -0.020 131.776 -0.020

Add all the adjusted EPS together and divide 10 will get our e10.


Nuo Therapeutics  (OTCPK:AURX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Nuo Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Nuo Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuo Therapeutics (Nuo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8285 El Rio, Suite 190, Houston, TX, USA, 77054
Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The Aurix product became commercially available for sale in current financial year.
Executives
Charles E Sheedy 10 percent owner TWO HOUSTON CENTER, SUITE 2907, HOUSTON TX 77010
David Emerson Jorden director, officer: CEO, CFO 2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381
Lawrence Atinsky director 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
C Eric Winzer director
Paul Mintz director C/O NUO THERAPEUTICS INC., 207A PERRY PARKWAY, SUITE 1, GAITHERSBURG MD 20877
Peter Clausen officer: CSO 11204 JEFFRO COURT, IJAMSVILLE MD 21754
Scott M. Pittman director 3683 JOHN NASH BLVD., BLUEFIELD WV 24701
Boyalife Investment Fund I, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Dean Tozer officer: CHIEF COMMERCIAL OFFICER C/O ADVANCED BIOHEALING, INC., 36 CHURCH LANE, WESTPORT CT 06880
Steven A Shallcross officer: SEE REMARKS C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Aldagen Holdings, Llc 10 percent owner, other: May be part of a 13(d) group C/O THOMAS A. ALLEN, ESQ., 4101 LAKE BOONE TRAIL, STE 300, RALEIGH NC 27607
Kathryne Carr 10 percent owner, other: May be part of a 13(d) group 315 OLD IVY WAY, SUITE 101, CHARLOTTESVILLE VA 22903
William W Brooke 10 percent owner, other: May be part of a 13(d) group 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Guercio Joseph Del director C/O CLARK INVESTMENTS, 7500 OLD GEORGETOWN ROAD, SUITE 620, BETHESDA MD 20814
B. Jefferson Clark 10 percent owner, other: May be part of a 13(d) group C/O ALDAGEN, INC., 2810 MERDIAN PARKWAY, SUITE 148, DURHAM NC 27713